Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic AB announced that its founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his groundbreaking work in Alzheimer’s research and the development of lecanemab. This recognition highlights BioArctic’s significant contributions to the field and underscores the potential impact of lecanemab in altering the course of Alzheimer’s disease, marking a paradigm shift in treatment possibilities.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. The company is known for developing Leqembi® (lecanemab), the first drug proven to slow Alzheimer’s disease progression and reduce cognitive impairment. BioArctic collaborates with Eisai and has a broad research portfolio, including Alzheimer’s, Parkinson’s, ALS, and enzyme deficiency diseases, utilizing proprietary BrainTransporter™ technology.
Average Trading Volume: 315,613
Current Market Cap: SEK15.57B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.